Healthcare / Medical Instruments & SuppliesNasdaqCM
$0.58
-0.01 (-1.69%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-8.6M · quality 58.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$63M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-68.1%
↓Gross Margin
22.1%
↓Debt/Equity
0.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+37.0%
FCF CAGR
—
FCF margin
-741.2%
FCF / Net income
0.64x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $872495.0 · net income $-10.0M · FCF $-6.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $872495.00 | $872495.00 | $29816.00 | $72855.00 | $339666.00 |
| Net Income | $-10.0M | $-10.0M | $-11.7M | $-14.4M | $-31.7M |
| EBITDA | $-9.3M | $-9.3M | $-11.1M | $-13.8M | $-31.0M |
| EPS | -0.10 | -0.10 | -0.12 | -0.14 | -0.34 |
| Gross Margin | 22.1% | 22.1% | -1010.4% | -1071.3% | -10.9% |
| Operating Margin | -1100.4% | -1100.4% | -40174.8% | -20112.5% | -3528.5% |
| Net Margin | -1150.7% | -1150.7% | -39254.1% | -19784.9% | -9330.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.05 | 0.05 | 0.06 | 0.05 | 0.05 |
| Current Ratio | 1.00 | 1.00 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-6.5M | $-6.5M | $-8.6M | $-15.2M | $-12.3M |
| Returns | |||||
| ROE | -68.1% | -68.1% | -58.0% | -47.4% | -76.3% |
| Valuation | |||||
| P/B | 4.06 | 4.06 | 5.63 | 5.20 | 6.83 |
| Growth & Yield | |||||
| Revenue Growth | 2826.3% | 2826.3% | -59.1% | -78.6% | — |
| EPS Growth | 16.7% | 16.7% | 14.3% | 58.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-61.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.12 → -0.10
Residual
-61.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.